IBD: 每天服用阿司匹林不会影响炎症性肠病患者的临床结局

2020-05-16 MedSci原创 MedSci原创

尽管有几项研究已将非甾体类抗炎药的使用与炎症性肠病(IBD)患者的疾病发作相关联,但对每日服用阿司匹林对IBD患者临床结局的影响知之甚少。

背景: 尽管有几项研究已将非甾体类抗炎药的使用与炎症性肠病(IBD)患者的疾病发作相关联,但对每日服用阿司匹林对IBD患者临床结局的影响知之甚少。本项研究旨在探究每天服用阿司匹林对炎症性肠病患者的临床结局的影响

方法: 研究人员对前瞻性收集的2008年5月至2015年6月IBD患者的登记资料进行了回顾性分析。每天使用阿司匹林的患者均按年龄,性别,疾病,疾病位置和是否存在阿司匹林进行了1:4匹配。最终分析中包括随访至少18个月的患者。主要观察结果是在随访期间进行了IBD相关的住院治疗,IBD相关的手术以及需要皮质类固醇治疗。

结果: 本项研究总共包括764例IBD患者,其中174例正在服用阿司匹林。两组之间的年龄,性别,诊断(克罗恩病与溃疡性结肠炎),疾病持续时间,查尔森合并症指数,吸烟状况,药物使用或基线C反应蛋白无统计学差异。在控制了整个人群的协变量和随访时间后,使用阿司匹林与IBD相关并发症住院的风险无关(几率[OR]为1.46;P = 0.10),皮质类固醇使用(OR ,例如0.99;P = 0.70)或进行了与IBD相关的手术(OR,0.99;P = 0.96)。

结论: 阿司匹林的使用不会影响IBD患者的主要临床结局。尽管在本研究中未直接评估阿司匹林对粘膜炎症的影响,但这些发现支持了该人群中每日服用阿司匹林的安全性。

原始出处:

Parita Patel. Et al. Daily Aspirin Use Does Not Impact Clinical Outcomes in Patients With Inflammatory Bowel Disease. Inflammatory Bowel Diseases.2020.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1843224, encodeId=c28d1843224f0, content=<a href='/topic/show?id=3d052296e4e' target=_blank style='color:#2F92EE;'>#临床结局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22967, encryptionId=3d052296e4e, topicName=临床结局)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7fbd46, createdName=mei531, createdTime=Thu Jun 11 02:55:17 CST 2020, time=2020-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1263569, encodeId=be2812635694e, content=<a href='/topic/show?id=75bc930217' target=_blank style='color:#2F92EE;'>#IBD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9302, encryptionId=75bc930217, topicName=IBD)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fc0372, createdName=bnurmamat, createdTime=Mon May 18 07:55:17 CST 2020, time=2020-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1547325, encodeId=df4d154e3257d, content=<a href='/topic/show?id=4ef26e01766' target=_blank style='color:#2F92EE;'>#炎症性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67017, encryptionId=4ef26e01766, topicName=炎症性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=09e813968720, createdName=12498dd9m15暂无昵称, createdTime=Mon May 18 07:55:17 CST 2020, time=2020-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1600055, encodeId=c3311600055ee, content=<a href='/topic/show?id=508e6e03203' target=_blank style='color:#2F92EE;'>#炎症性肠病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67032, encryptionId=508e6e03203, topicName=炎症性肠病患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9fa18776644, createdName=huangshifeng, createdTime=Mon May 18 07:55:17 CST 2020, time=2020-05-18, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1843224, encodeId=c28d1843224f0, content=<a href='/topic/show?id=3d052296e4e' target=_blank style='color:#2F92EE;'>#临床结局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22967, encryptionId=3d052296e4e, topicName=临床结局)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7fbd46, createdName=mei531, createdTime=Thu Jun 11 02:55:17 CST 2020, time=2020-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1263569, encodeId=be2812635694e, content=<a href='/topic/show?id=75bc930217' target=_blank style='color:#2F92EE;'>#IBD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9302, encryptionId=75bc930217, topicName=IBD)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fc0372, createdName=bnurmamat, createdTime=Mon May 18 07:55:17 CST 2020, time=2020-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1547325, encodeId=df4d154e3257d, content=<a href='/topic/show?id=4ef26e01766' target=_blank style='color:#2F92EE;'>#炎症性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67017, encryptionId=4ef26e01766, topicName=炎症性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=09e813968720, createdName=12498dd9m15暂无昵称, createdTime=Mon May 18 07:55:17 CST 2020, time=2020-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1600055, encodeId=c3311600055ee, content=<a href='/topic/show?id=508e6e03203' target=_blank style='color:#2F92EE;'>#炎症性肠病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67032, encryptionId=508e6e03203, topicName=炎症性肠病患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9fa18776644, createdName=huangshifeng, createdTime=Mon May 18 07:55:17 CST 2020, time=2020-05-18, status=1, ipAttribution=)]
    2020-05-18 bnurmamat
  3. [GetPortalCommentsPageByObjectIdResponse(id=1843224, encodeId=c28d1843224f0, content=<a href='/topic/show?id=3d052296e4e' target=_blank style='color:#2F92EE;'>#临床结局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22967, encryptionId=3d052296e4e, topicName=临床结局)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7fbd46, createdName=mei531, createdTime=Thu Jun 11 02:55:17 CST 2020, time=2020-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1263569, encodeId=be2812635694e, content=<a href='/topic/show?id=75bc930217' target=_blank style='color:#2F92EE;'>#IBD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9302, encryptionId=75bc930217, topicName=IBD)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fc0372, createdName=bnurmamat, createdTime=Mon May 18 07:55:17 CST 2020, time=2020-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1547325, encodeId=df4d154e3257d, content=<a href='/topic/show?id=4ef26e01766' target=_blank style='color:#2F92EE;'>#炎症性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67017, encryptionId=4ef26e01766, topicName=炎症性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=09e813968720, createdName=12498dd9m15暂无昵称, createdTime=Mon May 18 07:55:17 CST 2020, time=2020-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1600055, encodeId=c3311600055ee, content=<a href='/topic/show?id=508e6e03203' target=_blank style='color:#2F92EE;'>#炎症性肠病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67032, encryptionId=508e6e03203, topicName=炎症性肠病患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9fa18776644, createdName=huangshifeng, createdTime=Mon May 18 07:55:17 CST 2020, time=2020-05-18, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1843224, encodeId=c28d1843224f0, content=<a href='/topic/show?id=3d052296e4e' target=_blank style='color:#2F92EE;'>#临床结局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22967, encryptionId=3d052296e4e, topicName=临床结局)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7fbd46, createdName=mei531, createdTime=Thu Jun 11 02:55:17 CST 2020, time=2020-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1263569, encodeId=be2812635694e, content=<a href='/topic/show?id=75bc930217' target=_blank style='color:#2F92EE;'>#IBD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9302, encryptionId=75bc930217, topicName=IBD)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fc0372, createdName=bnurmamat, createdTime=Mon May 18 07:55:17 CST 2020, time=2020-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1547325, encodeId=df4d154e3257d, content=<a href='/topic/show?id=4ef26e01766' target=_blank style='color:#2F92EE;'>#炎症性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67017, encryptionId=4ef26e01766, topicName=炎症性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=09e813968720, createdName=12498dd9m15暂无昵称, createdTime=Mon May 18 07:55:17 CST 2020, time=2020-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1600055, encodeId=c3311600055ee, content=<a href='/topic/show?id=508e6e03203' target=_blank style='color:#2F92EE;'>#炎症性肠病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67032, encryptionId=508e6e03203, topicName=炎症性肠病患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9fa18776644, createdName=huangshifeng, createdTime=Mon May 18 07:55:17 CST 2020, time=2020-05-18, status=1, ipAttribution=)]

相关资讯

Lancet:P2Y12抑制剂 vs 阿司匹林用于脉粥样硬化患者二级预防

研究认为,与阿司匹林单药治疗相比, P2Y 12抑制剂单一疗法可降低动脉粥样硬化患者心肌梗死风险,但对全因和血管死亡率没有任何影响,P2Y 12抑制剂单一疗法的临床益处值得商榷

JGH OPEN:阿司匹林对胃癌的发生和生存的影响

最近发表的许多研究都在评估阿司匹林对胃癌的化学预防作用,因此,本研究旨在评估阿司匹林对胃癌发生和死亡的影响进行了荟萃分析。

Circulation:利伐沙班联合阿司匹林治疗对有PCI史的患者的预后的影响

COMPASS试验表明,相比单用阿司匹林(100mg,1/日),用利伐沙班(2.5mg,2/日)联合阿司匹林(100mg,1/日),双重途径抑制(DPI),可减少慢性冠状动脉综合征或周围动脉病患者的心

王海玲教授:高血压患者阿司匹林一级预防的风险评估

阿司匹林曾经广泛应用于动脉粥样硬化性心血管疾病(ASCVD)的一级预防。然而,近年来关于阿司匹林在ASCVD一级预防中的作用一直存在争议。2018年发表的ARRIVE、ASCEND和ASPREE三项重

Blood:三种阿司匹林治疗方案在优化特发性血小板增多症患者抗血小板治疗比较

目前推荐的用于心血管预防的75-100mg od的阿司匹林治疗方案在绝大多数ET患者中减少血小板活化方面存在较大的不足。小剂量阿司匹林的抗血小板效应可通过缩短给药间隔至12小时得到明显改善。

Blood:针对特发性血小板增多症,阿司匹林优化抗血小板疗法的更佳用药方案

特发性血小板增多症(ET)的特征是巨核细胞生成异常和血栓风险增加。推荐的抗血栓治疗方案:小剂量阿司匹林,每日一次(od);但加速血小板生成可能会缩短血小板环氧化酶(COX)-1抑制的持续时间。